JP7041298B2 - リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法 - Google Patents

リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法 Download PDF

Info

Publication number
JP7041298B2
JP7041298B2 JP2021035929A JP2021035929A JP7041298B2 JP 7041298 B2 JP7041298 B2 JP 7041298B2 JP 2021035929 A JP2021035929 A JP 2021035929A JP 2021035929 A JP2021035929 A JP 2021035929A JP 7041298 B2 JP7041298 B2 JP 7041298B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
lipoic acid
lace
choline ester
acid choline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2021035929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021147392A (ja
JP2021147392A5 (enExample
Inventor
リ ザイクシング
ムリダール ウェイコール リラダール
チュー ティンイング
バッチャー クリストフ
フルバッハ― ディートマー
フランツ クルーゲ ヨハネス
ソーレン ワースマン ジェンス
ゴーシュ マレー
ダグラス ファッチ エレミヤ
ライ マカリスター カール
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021147392A publication Critical patent/JP2021147392A/ja
Publication of JP2021147392A5 publication Critical patent/JP2021147392A5/ja
Priority to JP2021206074A priority Critical patent/JP2022058376A/ja
Application granted granted Critical
Publication of JP7041298B2 publication Critical patent/JP7041298B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021035929A 2020-03-13 2021-03-08 リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法 Expired - Fee Related JP7041298B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021206074A JP2022058376A (ja) 2020-03-13 2021-12-20 リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/079271 2020-03-13
CN2020079271 2020-03-13
US202063013836P 2020-04-22 2020-04-22
US63/013,836 2020-04-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021206074A Division JP2022058376A (ja) 2020-03-13 2021-12-20 リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法

Publications (3)

Publication Number Publication Date
JP2021147392A JP2021147392A (ja) 2021-09-27
JP2021147392A5 JP2021147392A5 (enExample) 2021-11-04
JP7041298B2 true JP7041298B2 (ja) 2022-03-23

Family

ID=75108681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021035929A Expired - Fee Related JP7041298B2 (ja) 2020-03-13 2021-03-08 リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法
JP2021206074A Pending JP2022058376A (ja) 2020-03-13 2021-12-20 リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021206074A Pending JP2022058376A (ja) 2020-03-13 2021-12-20 リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法

Country Status (18)

Country Link
US (2) US11135239B1 (enExample)
EP (1) EP4118079A1 (enExample)
JP (2) JP7041298B2 (enExample)
KR (1) KR20220146561A (enExample)
CN (2) CN113387923A (enExample)
AU (1) AU2021235563A1 (enExample)
BR (1) BR112022018043A2 (enExample)
CA (1) CA3175077A1 (enExample)
CO (1) CO2022012653A2 (enExample)
CR (1) CR20220449A (enExample)
DO (1) DOP2022000179A (enExample)
EC (1) ECSP22069611A (enExample)
IL (1) IL295378A (enExample)
JO (1) JOP20220211A1 (enExample)
MX (1) MX2022011206A (enExample)
PE (1) PE20230242A1 (enExample)
TW (1) TWI768760B (enExample)
WO (1) WO2021181361A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024240216A1 (zh) 2023-05-24 2024-11-28 温州医科大学附属眼视光医院 一种有效延缓及治疗近视的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053646A1 (en) 2015-09-24 2017-03-30 Encore Vision, Inc. Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
WO2018055572A1 (en) 2016-09-23 2018-03-29 Encore Vision, Inc. Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520920A (en) 1978-07-31 1980-02-14 Honda Motor Co Ltd Device for absorbing twisting vibration of drive system
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
EP2442647B1 (en) 2009-06-15 2016-03-16 Encore Health LLC Dithiol compounds, derivatives, and uses therefor
DK2442645T3 (en) 2009-06-15 2014-11-24 Encore Health Llc choline
MX384877B (es) * 2014-03-03 2025-03-14 Novartis Ag Composiciones de éster de colina de ácido lipoico y métodos de uso.
WO2016126662A1 (en) 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2016176089A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN106967044B (zh) * 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
SG11202006492SA (en) * 2018-02-05 2020-08-28 Cellix Bio Private Ltd Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
US11158871B2 (en) 2018-07-18 2021-10-26 GM Global Technology Operations LLC Fuel cell assembly and a vehicle that utilizes the fuel cell assembly
US11985964B2 (en) 2018-08-03 2024-05-21 Kevin F Lohmeier Fishing rod holder
CN108586429A (zh) 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法
CN108822077A (zh) 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053646A1 (en) 2015-09-24 2017-03-30 Encore Vision, Inc. Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
WO2018055572A1 (en) 2016-09-23 2018-03-29 Encore Vision, Inc. Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products

Also Published As

Publication number Publication date
CN113387923A (zh) 2021-09-14
TW202140435A (zh) 2021-11-01
JP2021147392A (ja) 2021-09-27
ECSP22069611A (es) 2022-10-31
US20210283171A1 (en) 2021-09-16
CO2022012653A2 (es) 2022-09-09
US11135239B1 (en) 2021-10-05
US20210393671A1 (en) 2021-12-23
US11590158B2 (en) 2023-02-28
CN115279745A (zh) 2022-11-01
WO2021181361A1 (en) 2021-09-16
BR112022018043A2 (pt) 2022-10-18
PE20230242A1 (es) 2023-02-07
CA3175077A1 (en) 2021-09-16
EP4118079A1 (en) 2023-01-18
MX2022011206A (es) 2022-09-19
CR20220449A (es) 2022-10-12
IL295378A (en) 2022-10-01
KR20220146561A (ko) 2022-11-01
JOP20220211A1 (ar) 2023-01-30
TWI768760B (zh) 2022-06-21
JP2022058376A (ja) 2022-04-12
DOP2022000179A (es) 2022-09-30
AU2021235563A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
KR102357471B1 (ko) 중수소 농축 N-아세틸시스테인 아미드(D-NACA) 및 (2R,2R')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(Di-NACA)의 제조방법 및 산화 스트레스를 포함하는 질환을 치료하기 위한 D-NACA 및 Di-NACA의 사용방법
KR102349776B1 (ko) 눈 질환의 치료를 위한 조성물 및 방법
US20220096434A1 (en) Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
JP5921439B2 (ja) 結晶形態ｉｉの７−［３，５−ジヒドロキシ−２−（３−ヒドロキシ−５−フェニル−ペント−１−エニル）−シクロペンチル］−ｎ−エチル−ヘプト−５−エナミド（ビマトプロスト）、その調製方法、およびその使用方法
JP7041298B2 (ja) リポ酸コリンエステル塩の医薬組成物及びそれを使用した処置方法
US20230135366A1 (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
JPH0427976B2 (enExample)
JP7250685B2 (ja) ピリジルアミノ酢酸化合物を含有する医薬
JP3094233B2 (ja) （ｓ）−チモロール半水和物を含有する局所眼科治療用組成物及びその製造方法
JP2021147392A5 (enExample)
US5496820A (en) Ophthalmic use of S-timolol hemihydrate
JP4826051B2 (ja) スチルベン誘導体の新規結晶及びその製造方法
WO2013114397A2 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
EP4157266B1 (en) Crystalline forms of solvates of tryptophan derivatives, compositions comprising them and uses thereof
WO2022107791A1 (ja) ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液
AU2023334383A1 (en) Varenicline related compounds and methods for treating diseases and conditions including tobacco use disorder
JP2025538598A (ja) ピリジンフェニル化合物を含有する眼科用製剤、その調製方法および使用
CA3191776A1 (en) Salts of fenfluramine
JP2025519424A (ja) ベンジルアトロピンを含む水性医薬組成物及びその使用
HK40089977A (en) Crystalline forms of solvates of tryptophan derivatives, compositions comprising them and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210817

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220310

R150 Certificate of patent or registration of utility model

Ref document number: 7041298

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees